Benznidazole - Savant HWP/KaloBios

Drug Profile

Benznidazole - Savant HWP/KaloBios

Alternative Names: HWP-002

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator Savant HWP
  • Developer KaloBios Pharmaceuticals; Savant HWP
  • Class Antiprotozoals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chagas disease

Most Recent Events

  • 06 Apr 2017 KaloBios announces intention to submit NDA to the US FDA for Chagas disease in 2018
  • 06 Apr 2017 KaloBios intends to submit IND to the US FDA for Chagas disease in May 2017
  • 01 Jan 2017 The US FDA accepts the 505(b) pathway for benznidazole (914437)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top